Upfront window trial of topotecan in previously untreated children and adolescents with poor prognosis metastatic osteosarcoma: Children's Cancer Group (CCG) 7943 Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Bone Neoplasms
  • Osteosarcoma
  • Topotecan

abstract

  • Topotecan at dose of 3.5 mg/m(2)/day can be safely administered upfront to newly diagnosed patients without excessive toxicity. Insufficient activity was seen with topotecan in this schedule to warrant further studies in osteosarcoma. The combination of ICE and CD was tolerable when delivered after initial topotecan therapy.

publication date

  • April 15, 2007

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1002/cncr.22553

PubMed ID

  • 17334983

Additional Document Info

start page

  • 1646

end page

  • 53

volume

  • 109

number

  • 8